MacTel is a rare, progressive eye disease that affects the macula and causes a gradual deterioration in central vision.
Medical Device Network on MSN2d
Perfuse announces Phase I/IIa trial data of intravitreal implant for glaucomaThe implant is engineered to offer PER-001’s sustained release, aiming for a “convenient” dosing frequency of every six ...
Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced that the U.S. Food and Drug Administration (FDA), has ...
Retinal implants have gained increasing interest since it was demonstrated in acute trials that completely blind subjects do have light perception upon electrical stimulation of the inner surface ...
Rhian Lewis, 50, uses a pointer to interpret the images her retinal implant sends to her brain as research optometrist Charles Cottriall, of England’s Oxford Eye Hospital, looks on. Patients ...
New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...
Hosted on MSN2mon
Retinal Health Matters: Key insights on disorders and treatmentsWhile there is currently no cure for RP, certain treatments such as gene therapy, retinal implants, and vitamin A supplementation can help slow its progression. Ongoing research in areas like stem ...
The 1 failure in group 1A had an IOP of 25 mm Hg. Of the 3 failures in group 2, 1 had an IOP of 20, 1 had an inoperable retinal detachment, and 1 developed phthisis bulbi. For patients in group 1A ...
Warnings and Precautions: The SUSVIMO implant and the procedures associated ... macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME ...
Phase 3 trials demonstrated ENCELTO significantly slowed macular photoreceptor loss in MacTel patients over 24 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback